Nassr Nassr

Why was the study undertaken? To evaluate the safety, tolerability and clinical efficacy of balinatunfib versus placebo in patients with mild-to-moderate psoriasis Balinatunfib is the first orally administered small molecule that specifically inhibits TNFR1 signalling What does this study add? The results of this study indicate that balinatunfib treatment was tolerable with no serious or severe TEAEs in patients with mild-to-moderate psoriasis.

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Biologic tumor necrosis factor α (TNF-α) inhibitors have emerged as therapeutic agents for the treatment of various inflammatory diseases. However, severe adverse effects with biologics led to further research. Oral small molecule inhibitors of human TNF might evolve as novel therapeutic agents for the treatment of these diseases with a differentiated profile based on the selective TNFR1 inhibition and sparing of TNFR2 signaling.